近年来，全球结直肠癌（CRC）和乳腺癌（BC）的发病率增加，因缺乏选择性抗肿瘤疗法导致死亡率上升。目前的化疗和手术干预是治疗晚期CRC或BC的首选疗法，但晚期CRC和BC患者的预后仍然很差。嵌合抗原受体（CAR）-T细胞免疫疗法在治疗血液恶性肿瘤时取得了显著的临床效果。新型CAR-T疗法的靶抗原包括GUCY2C，CLEC14A，CD26，TEM8/ANTXR1，PDPN，PTK7，PODXL，CD44，CD19，CD20，CD22，BCMA，GD2，Mesothelin，TAG-72，CEA，EGFR，B7H3，HER2，IL13Ra2，MUC1，EpCAM，PSMA，PSCA，NKG2D。本综述的重要目标是探讨与CRC和BC相关的几个新型CAR-T靶点的最新信息。我们生动地描述了治疗CRC或BC时CAR-T疗法面临的挑战。实体肿瘤的免疫抑制微环境、肿瘤特异性抗原的缺乏以及治疗后的副作用是推动CAR-T细胞发展的主要障碍。已经有几个与CRC或BC的CAR-T免疫疗法相关的临床试验正在进行中。这篇综述有助于学者、临床医生和临床肿瘤学家了解更多有关新型CAR-T靶点的知识，并在该疗法中克服所面临的挑战。© 2023. 波兰弗罗茨瓦夫的L. Hirszfeld免疫学与实验疗法研究所。

In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has increased worldwide and caused a higher mortality rate due to the lack of selective anti-tumor therapies. Current chemotherapies and surgical interventions are significantly preferred modalities to treat CRC or BC in advanced stages but the prognosis for patients with advanced CRC and BC remains dismal. The immunotherapy technique of chimeric antigen receptor (CAR)-T cells has resulted in significant clinical outcomes when treating hematologic malignancies. The novel CAR-T therapy target antigens include GUCY2C, CLEC14A, CD26, TEM8/ANTXR1, PDPN, PTK7, PODXL, CD44, CD19, CD20, CD22, BCMA, GD2, Mesothelin, TAG-72, CEA, EGFR, B7H3, HER2, IL13Ra2, MUC1, EpCAM, PSMA, PSCA, NKG2D. The significant aim of this review is to explore the recently updated information pertinent to several novel targets of CAR-T for CRC, and BC. We vividly described the challenges of CAR-T therapies when treating CRC or BC. The immunosuppressive microenvironment of solid tumors, the shortage of tumor-specific antigens, and post-treatment side effects are the major hindrances to promoting the development of CAR-T cells. Several clinical trials related to CAR-T immunotherapy against CRC or BC have already been in progress. This review benefits academicians, clinicians, and clinical oncologists to explore more about the novel CAR-T targets and overcome the challenges during this therapy.© 2023. L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.